Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fructose study aims to uncover hidden link to prediabetes

NCT ID NCT04168372

Knowledge-focused Sponsor: Touro University, California Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study looks at how fructose in meals influences fat production and blood sugar levels in people with prediabetes or insulin resistance. Researchers will give participants special labeled fructose or pyruvate in liquid meals to track these processes. The goal is to better understand the mechanisms behind fructose's role in metabolic issues.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
fructose
What this could lead to
If successful, this could help explain how fructose contributes to prediabetes and insulin resistance, pointing toward dietary recommendations.
What could go wrong
This is a small, early-stage observational study with only 35 participants, so results may not apply broadly. It measures biological markers, not health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

35 people

The number who actually took part.

Started

Sep 2019

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Body Mass Index 22 to 35 kg/m2 * Prediabetic (HbA1c 5.7% to 6.5%) or hyperinsulinemic (fasting insulin ≥12 µIU/mL) but non-diabetic (fasting glucose \<126mg/dL and HbA1c \< 6.5%) ; or normal control (fasting insulin \<10 µIU/mL, fasting glucose \<100 mg/dL, and HbA1c \< 5.7%) Exclusion Criteria: * Pregnancy or lactation within the past six months * Type 1 or 2 diabetes mellitus * History of liver disease or aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 2x the upper limit of normal (ULN); * Fasting triglyceride or total cholesterol levels above 95th percentile for age and sex; * Hemoglobin or hematocrit below the lower limit of normal for sex; * Report of hepatitis or HIV infection; * History of cancer, use of any anti-diabetic medications or hypolipidemic agents in the past six months; * History of surgical procedure for obesity; * Self-reported change in body weight \>5% in the past six months; * History of other conditions known to affect insulin sensitivity and lipid metabolism; * Known intolerance to acetaminophen or components of the liquid test meals.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hyperinsulinemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glucose intolerance hyperinsulinism Insulin Resistance prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Insulin resistance Insulin sensitivity Pre diabetes

Contacts and locations

Locations

  • Touro University California

    Vallejo, California, 94592, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.